Tania Riddell

• University of Auckland

Aim: In Aotearoa, New Zealand, cardiovascular disease (CVD) burden is greatest among Indigenous Māori, Pacific and Indian people. The aim of this study was to describe CVD risk profiles by ethnicity. Methods: We conducted a cross-sectional analysis of a cohort of people aged 35-74 years who had a CVD risk assessment in primary care between 2004...

Background: Most cardiovascular disease risk prediction equations in use today were derived from cohorts established last century and with participants at higher risk but less socioeconomically and ethnically diverse than patients they are now applied to. We recruited a nationally representative cohort in New Zealand to develop equations relevant...

Introduction: National cardiovascular disease (CVD) guidelines recommend that adults have cholesterol levels monitored regularly. However, little is known about the extent and equity of cholesterol testing in New Zealand. Aim: To investigate the distribution and frequency of blood lipid testing by sociodemographic status in Auckland, New Zealand...

Background: Triple therapy with anti-platelet/anti-coagulant, blood pressure (BP)-lowering, and statin medications improves outcomes in atherosclerotic cardiovascular disease (CVD). However, in practice there is often a substantial evidence-practice gap, with sub-optimal initiation and longer-term adherence. Our aim was to enumerate a contemporary...

Objectives: To determine 28-day and one-year case fatality in patients hospitalised with acute coronary syndromes (ACS) and identify factors associated with mortality. Methods: All New Zealand residents admitted with ACS between 2007 and 2009 were followed for one year using individual patient linkage of national hospitalisation and mortality da...

Prior studies have reported higher rates of coronary revascularisation in European compared with Maori and Pacific patients. Our aim was to define the current variation by ethnicity in investigation, revascularisation and pharmacotherapy after admission with an acute coronary syndrome (ACS). Data from consecutive New Zealand residents <80 years of...

Introduction: Glycosylated haemoglobin (HbA 1c ) has recently been accepted for diagnosing diabetes in New Zealand. A 2 hour 75g oral glucose test was used previously and remains an alternative for diagnosis. Hypothesis: We assessed the hypothesis that HbA 1c would do at least as well as fasting and 2 hour glucose levels for predicting vascular eve...

Aim: To examine whether use of a standardized cardiovascular disease (CVD) risk assessment recommended by national guidelines is associated with appropriate initiation and maintenance of medication in a large primary care cohort. Methods and design: A total of 90,631 people aged 30-80 years were followed for up to 3 years after a formal CVD risk...

To describe patterns of statin use and predictors of poor maintenance over a 3-year period following an acute coronary syndrome (ACS). National hospitalisation, mortality and pharmaceutical dispensing data were linked for all subjects aged 35-84 years discharged from a public hospital with an ACS in New Zealand in 2007. A Medication Possession Rati...

Cardiovascular disease (CVD) is a major cause of death and hospitalization in New Zealand, and there is evidence that some population groups are at greater risk than others, even after analyses adjust for clinical (e.g., high blood pressure, diabetes, cholesterol, smoking) and socio-demographic risk factors. The increasing availability of complex h...

New Zealand (NZ) guidelines recommend treating people for cardiovascular disease (CVD) risk on the basis of five-year absolute risk using a NZ adaptation of the Framingham risk equation. A diabetes-specific Diabetes Cohort Study (DCS) CVD predictive risk model has been developed and validated using NZ Get Checked data. To revalidate the DCS model w...

To compare the cardiovascular disease (CVD) risk profiles of Indian and European patients from routine primary care assessments in the northern region of New Zealand. Anonymous CVD risk profiles were extracted from PREDICT (a web-based decision support program) for Indian and European patients aged 35-74 years. Linear regression models were used to...

Blood pressure-lowering (BPL) and lipid-lowering (LL) medications together reduce estimated absolute five-year cardiovascular disease (CVD) risk by >40%. International studies indicate that the proportion of people with CVD receiving pharmacotherapy increases with advancing age. To compare BPL and LL medications, by sociodemographic characteristics...

To estimate sociodemographic differences in the prevalence of coronary heart disease (CHD) in New Zealand from linked health records. We combined records of hospital treatment for CHD, dispensing of selected anti-anginal drugs and mortality to estimate the national point prevalence of coronary heart disease in New Zealand in December 2008. Stratifi...

Data on the cardiovascular disease risk profiles of Pacific peoples in New Zealand is usually aggregated and treated as a single entity. Little is known about the comparability or otherwise of cardiovascular disease (CVD) risk between different Pacific groups. To compare CVD risk profiles for the main Pacific ethnic groups assessed in New Zealand p...

Ischaemic Heart Disease (IHD) is a leading cause of death in New Zealand and the burden falls disproportionately on Māori, the indigenous population of Aotearoa New Zealand. Data for Māori:non-Māori disparities in risk factors, hospitalisation, procedure receipt and mortality for IHD are analysed. Age-adjusted rates of IHD mortality (2000-2004) and...

This study estimated diabetes prevalence and utilisation of healthcare services in Counties Manukau using routinely collected administrative data and compared estimates with findings for three other district health boards (DHBs) in close geographic proximity. Records of subsidy claims for pharmaceuticals and laboratory investigations were linked to...

Rates of acute rheumatic fever and chronic rheumatic heart disease in Aboriginal people, Torres Strait Islanders and Māori continue to be unacceptably high. The impact of rheumatic heart disease is inequitable on these populations as compared with other Australians and New Zealanders. The associated cardiac morbidity, including the development of r...

The challenges and opportunities for provision of, and access to, reliable chronic cardiovascular health care for Indigenous people were addressed by expert speakers from New Zealand and Australia. It is well recognised that cardiovascular disease is a life-long concern, requiring reliable follow-up, early transition of clinical research into pract...

To compare the calibration performance of the original Framingham Heart Study risk prediction score for cardiovascular disease and an adjusted version of the Framingham score used in current New Zealand cardiovascular risk management guidelines for high and low risk ethnic groups. Since 2002 cardiovascular risk assessments have been undertaken as p...

To investigate the differences in the baseline cardiovascular disease (CVD) risk profiles of Pacific peoples and Europeans assessed in routine primary care practice by PREDICT, a web-based clinical decision support programme for assessing and managing CVD risk. PREDICT has been implemented in primary care practices from nine consenting PHOs in Auck...

To estimate coronary heart disease (CHD) incidence, prevalence, survival, case fatality and mortality for Māori, in order to support service planning and resource allocation. Incidence was defined as first occurrence of a major coronary event, i.e. the sum of first CHD hospital admissions and out-of-hospital CHD deaths in people without a hospital...

QRISK is better on every performance measure, and should be recommended in the UK

To describe the prevalence of cardiovascular disease (CVD) in New Zealand by ethnicity and socioeconomic status using NHI-linked electronic national databases. CVD prevalence by ethnicity and socioeconomic status in New Zealand in 2006/07 were estimated from national datasets of public hospital discharges, mortality registrations, and pharmaceutica...

To investigate the burden of modifiable cardiovascular disease (CVD) risk factors in patients admitted to coronary care by age, ethnicity, and socioeconomic status. Cross-sectional study of patients presenting to the Middlemore Hospital Coronary Care Unit with an acute CVD event from July 2004 to June 2006. CVD risk factor data was electronically c...

Accurate ethnicity data are a prerequisite for evidence-based cardiovascular risk assessment and management according to national guidelines. (i) To investigate the accuracy of ethnicity data in primary care medical records by comparing them with self-identified ethnicity. (ii) To determine the clinical impact of ethnicity misclassification on card...

Cardiovascular disease (CVD) prevention guidelines typically dichotomise patients by history of CVD, as patients with prior CVD are assumed to be at high CVD risk, whatever their CVD risk profiles. To assess the appropriateness of this practice by comparing CVD event rates of patients with and without prior CVD, over and above risk predicted by sta...

Computerised clinical decision support systems require health data to be captured in an explicit, structured way. However, traditional patient medical records contain data that is recorded in multiple ways using coding systems, free text, medical jargon and idiosyncratic abbreviations. To be meaningful, data transferred either automatically or manu...

Objective: To describe the patterns of adoption and use of PREDICT-CVD, a web-based decision support system for CVD risk assessment and management. Setting: General practices affiliated with ProCare Health Ltd, a network of three Auckland-based Primary Health Organisations. Population: Approximately 500 general practitioners (GPs) and 450 practic...

Current New Zealand cardiovascular (CVD) risk management guidelines advocate targeting treatment to patients with a high 5-year CVD risk assessed using a calculator derived from the Framingham Heart Study. For some high-risk population subgroups, a 5% upward adjustment to their calculated 5-year CVD risk is recommended. We estimated the impact of t...

To describe the cardiovascular disease risk factor status and risk management of Māori compared with non-Māori patients opportunistically assessed in routine practice using PREDICT-CVD, an electronic clinical decision support programme. In August 2002, a primary healthcare organisation, ProCare, implemented PREDICT-CVD as an opportunistic cardiovas...

To describe the cardiovascular disease (CVD) risk factor status of approximately 18,000 patients profiled in routine primary care practice by PREDICT-CVD, a web-based clinical decision support program for assessing and managing CVD risk. Between 2002 and 2005, 31,241 CVD risk assessments of 18,260 patients were undertaken in ProCare, a large primar...

To determine the effectiveness of a mobile phone text messaging smoking cessation programme. Randomised controlled trial New Zealand 1705 smokers from throughout New Zealand who wanted to quit, were aged over 15 years, and owned a mobile phone were randomised to an intervention group that received regular, personalised text messages providing smoki...

To determine whether a smoking cessation service using mobile phone text messaging is as effective for Maori as non-Maori. A single-blind randomised controlled trial was undertaken with recruitment targeted to maximise the participation of young Maori. The intervention included regular, personalised text messages providing smoking cessation advice,...

To examine the association between socioeconomic deprivation and heart failure outcomes in Maori and non-Maori New Zealanders. Retrospective analysis of heart failure mortality and hospital admissions among Maori and non-Maori aged 45 year and older assigned to small area deprivation (NZDep91/96) during the period 1988-1998. Deprivation was associa...

An open access copy of this article is available and complies with the copyright holder/publisher conditions. Aims: To determine whether a smoking cessation service using mobile phone text messaging is as effective for Maori as non-Maori. Methods: A single-blind randomised controlled trial was undertaken with recruitment targeted to maximise the pa...

To identify factors associated with patient referral to, uptake of, and completion of cardiac rehabilitation programmes in New Zealand. Information was collected on referrals to cardiac rehabilitation during February 2002. Routinely collected hospitalisation data were obtained for men and women aged over 35 years with specified coronary episodes. T...

To determine the extent to which Auckland general practitioners (GPs) follow Ministry of Health guidelines recommending the administration of pre-hospital antibiotic treatment to suspected cases of meningococcal disease. Retrospective audit of notified cases of meningococcal disease referred by Auckland GPs from 1 May 2001 to 30 April 2002. Of 142...